Profile of Depressive Symptoms in Parkinsons Disease

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

NCT02177357 ·Status: COMPLETED ·Phase: PHASE3

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

NCT02233023 ·Status: COMPLETED ·Phase: PHASE4

Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease

NCT00240409 ·Status: COMPLETED ·Phase: PHASE3

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

NCT00096720 ·Status: COMPLETED ·Phase: PHASE2

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

NCT00148486 ·Status: COMPLETED ·Phase: PHASE2

Study of Antidepressants in Parkinson's Disease

NCT00086190 ·Status: COMPLETED ·Phase: PHASE3

Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease

NCT05709301 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

NCT00479401 ·Status: COMPLETED ·Phase: PHASE3

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

NCT02236728 ·Status: COMPLETED

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

NCT00163085 ·Status: COMPLETED ·Phase: PHASE2

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

NCT00623324 ·Status: COMPLETED ·Phase: PHASE2

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

NCT01523301 ·Status: COMPLETED ·Phase: PHASE4

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

NCT00558025 ·Status: COMPLETED ·Phase: PHASE3

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

NCT00335166 ·Status: COMPLETED ·Phase: PHASE3

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

NCT01673724 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate in Patients With Parkinsonian Type Disorders

NCT03683225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

NCT02172573 ·Status: COMPLETED ·Phase: PHASE3

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

NCT02157714 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310 ·Status: RECRUITING ·Phase: PHASE3

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

NCT01227265 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

NCT00321854 ·Status: COMPLETED ·Phase: PHASE4

Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

NCT01538329 ·Status: COMPLETED ·Phase: PHASE2

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

NCT00601523 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

NCT03019289 ·Status: COMPLETED ·Phase: PHASE1